We believe the fact that our control cohort is heterogeneous represents strength, because it includes patients considered at high risk for BRCA1/2 mutation and those without any established risk factors for ovarian cancer, reflecting the baseline risk group (general population). This evidence concerns the gene BRCA1 and ovarian carcinoma.